Surveillance for hepatocellular carcinoma

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 5, 2014, Pages 783-793

  Sherman, Morris ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alpha fetoprotein; Cancer screening; Desgamma carboxy prothrombin; Hepatocellular carcinoma; Ultrasonography

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; DISEASE SURVEILLANCE; ECHOGRAPHY; HEALTH CARE COST; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; MORTALITY; ORGANIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; CARCINOMA, HEPATOCELLULAR; COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; HEALTH SURVEY; LIVER NEOPLASMS; METABOLISM; PROCEDURES;

ALPHA FETOPROTEIN;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; POPULATION SURVEILLANCE;

EID: 84921825164     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.08.008     Document Type: Review

References (63)

1. Furlan A, Marin D, Agnello F, Di Martino M, Di Marco V, Lagalla R, et al. Hepatocellular carcinoma presenting at contrastenhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (-2 cm) , indeterminate nodule: Growth rate and optimal interval time for imaging follow-up. J Comput Assist Tomogr 2012 Jan-Feb; 36 (1) : 20-5.
2. Taouli B, Goh JS, Lu Y, Qayyum A, Yeh BM, Merriman RB, et al. Growth rate of hepatocellular carcinoma: Evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 2005 JuleAug; 29 (4) : 425-9.
3. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992 Jul; 16 (1) : 132-7.
4. Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985 Aug; 89 (2) : 259-66.
5. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC, et al. Screening for liver cancer: Results of a randomised controlled trial in Qidong, China. J Med Screen 2003; 10: 204-9.
6. Yang B, Zhang B, Xu Y, Wang W, Shen Y, Zhang A, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123: 357-60.
7. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-22.
8. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
9. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.
10. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
11. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: Is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology 2011 Dec; 54 (6) : 1998-2004.
12. Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, Chen SL, et al. Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology 2014; 59: 1840-9.
13. Tong MJ, Sun HE, Hsien C, Lu DS. Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: Results from a community-based clinic. Dig Dis Sci 2010 Mar; 55 (3) : 826-35.
14. H1 Tanaka, Nouso K, Kobashi H, Kobayashi Y, Nakamura S, Miyake Y, et al. Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival. Liver Int 2006 Jun; 26 (5) : 543-51.
15. Wong GL, Wong VW, Tan GM, Ip KI, Lai WK, Li YW, et al. Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis. Liver Int 2008 Jan; 28 (1) : 79-87.
16. Taura N, Hamasaki K, Nakao K, Ichikawa T, Nishimura D, Goto T, et al. Clinical benefits of hepatocellular carcinoma surveillance: A single-center, hospital-based study. Oncol Rep 2005 Oct; 14 (4) : 999-1003.
17. Chan AC, Poon RT, Ng KK, Lo CM, Fan ST, Wong J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann Surg 2008 Apr; 247 (4) : 666-73.
18. Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol 1992 Sep-Oct; 7 (5) : 463-82. Sarasin Am J Med 1996.
19. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: A cost-utility analysis. Am J Gastroenterol 2003 Mar; 98 (3) : 679-904. Saab et al Liver Transpl 2003.
20. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004 Jun 1; 19 (11) : 1159-726.
21. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2008 Dec; 6 (12) : 1418-24.
22. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996 Oct; 101 (4) : 422-34.
23. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005 Jan; 3 (1) : 75-849.
24. Nouso K, Tanaka H, Uematsu S, Shiraga K, Okamoto R, Onishi H, et al. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances. J Gastroenterol Hepatol 2008 Mar; 23 (3) : 437-44.
25. Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, et al. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. J Hepatol 2012 May; 56 (5) : 1089-96.
26. Thompson Coon J, Rogers G, Hewson P, Wright D, Anderson R, Jackson S, et al. Surveillance of cirrhosis for hepatocellular carcinoma: A cost-utility analysis. Br J Cancer 2008 Apr 8; 98 (7) : 1166-75.
27. Cavazza A, Caballería L, Floreani A, Farinati F, Bruguera M, Caroli D, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers. Hepatology 2009 Oct; 50 (4) : 1162-8.
28. Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology 2008 Sep; 48 (3) : 863-70.
29. Yuen MF, Tanaka D, Fong YT, Fung J, Wong DHK, Yuen JCH, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatology 2009; 50: 80-8.
30. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol 2010; 28: 1660-5.
31. Yang HI, Yeun MF, Chan HLK, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) : Development and validation of a predictive score. Lancet Oncol 2011; 12: 568-74.
32. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol 2010 May 10; 28 (14) : 2437-44.
33. Sam JJ, Heathcote EJ, Wong DKH, Wooster DL, Shah H. Hepatitis B learning needs assessment of family medicine trainees in Canada: Results of a nationwide survey. Can J Gastroenterol 2011 Mar; 25 (3) : 127-34.
34. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009 Jan; 136 (1) : 138-48.
35. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: A Danish nationwide cohort study. Ann Intern Med 2012; 156: 841-7.
36. Gronbaek L, Vilstrup H, Jepsen P. autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis and causes of death. A nationwide registry-based cohort study. J Hepatol 2014; 60: 612-7.
37. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 2001 Apr; 34 (4) : 570-5.
38. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis. Gut 2001 Feb; 48 (2) : 251-9.
39. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G, et al. Screening for hepatocellular carcinoma in patients with Child's Acirrhosis: An 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994 Dec; 21 (6) : 1029-34.
40. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology 2014 May; 146 (5) : 1249-55.
41. Richardson P, Duan Z, Kramer J, Davila JA, Tyson GL, El-Serag HB. Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients. Clin Gastroenterol Hepatol 2012 Apr; 10 (4) : 428-33.
42. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol 2005 Sep; 43 (3) : 434-41.
43. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients. Cancer 2001 Feb 1; 91 (3) : 561-9.
44. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and desgamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007 Mar; 52 (3) : 776-82.
45. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010 Feb; 138 (2) : 493-502.
46. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012 Jan; 107 (1) : 64-74.
47. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006 Sep; 101 (9) : 2038-43.
48. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998 May 1; 82 (9) : 1643-8.
49. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, et al., Collaborative Hepato-Oncology Study Group of Japan. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001 Dec; 16 (12) : 1378-83.
50. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, Reddy KR, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 2007 Oct; 102 (10) : 2196-205.
51. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995 Aug; 22 (2) : 432-8.
52. Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: Effects on cancer stage and patient survival (Italian experience) . Am J Gastroenterol 2002 Mar; 97 (3) : 734-44.
53. Ando E, Kuromatsu R, Tanaka M, Takada A, Fukushima N, Sumie S, et al. Surveillance program for early detection of hepatocellular carcinoma in Japan: Results of specialized department of liver disease. J Clin Gastroenterol 2006 Nov-Dec; 40 (10) : 942-8.
54. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996 Sep 1; 78 (5) : 977-85.
55. Han KH, Kim Do Y, Park JY, Ahn SH, Kim J, Kim SU, et al. Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: A 15-year prospective study. J Clin Gastroenterol 2013 Jul; 47 (6) : 538-44.
56. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3-and 6-month periodicities. Hepatology 2011 Dec; 54 (6) : 1987-97.
57. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of earlyhepatocellular carcinoma and patient survival. J Hepatol 2010 Aug; 53 (2) : 291-7.
58. Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, et al. Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis: A randomized study in community. Am J Gastroenterol 2013 Mar; 108 (3) : 416-24.
59. Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008 Jan; 47 (1) : 97-104.
60. Khalili K, Kim TK, Jang HJ, Haider MA, Khan L, Guindi M, et al. Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization. J Hepatol 2011 Apr; 54 (4) : 723-8.
61. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010 May; 59 (5) : 638-44.
62. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: A meta-analysis. PLoS Med 2014 Apr 1; 11 (4) : E1001624.
63. Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: A systematic review. Ann Intern Med 2014 Aug 19; 161 (4) : 261-9.